Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

241. Review: most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children

Review: most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children Review: most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: most selective serotonin reuptake inhibitors lead to adverse events that appear to outweigh the benefits in children Article Text Treatment Review: most selective serotonin reuptake inhibitors lead

Evidence-Based Nursing (Requires free registration)2005

242. The investigation and analysis of critical incidents and adverse events in healthcare

The investigation and analysis of critical incidents and adverse events in healthcare The investigation and analysis of critical incidents and adverse events in healthcare Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information

NIHR HTA programme2005

243. The Research on Adverse Drug Events and Reports (RADAR) project.

The Research on Adverse Drug Events and Reports (RADAR) project. CONTEXT: In 1998, a multidisciplinary team of investigators initiated RADAR (Research on Adverse Drug events And Reports), a clinically based postmarketing surveillance program that systematically investigates and disseminates information describing serious and previously unrecognized adverse drug and device reactions (ADRs). OBJECTIVE: To describe the structure, operations, and preliminary findings from the RADAR project (...) and related dissemination efforts by pharmaceutical suppliers and the US Food and Drug Administration (FDA). DESIGN: After identifying a serious and unexpected clinical event suitable for further investigation, RADAR collaborators postulated clinical hypotheses and derived case series and incidence estimates from physician queries, published and unpublished clinical trials, published case reports, FDA databases, and manufacturer sales figures. RESULTS: RADAR investigators identified 16 types of serious

JAMA2005

244. Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events

Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events van Iersel MB, Zuidema SU, Koopmans RT, Verhey FR, Rikkert MG CRD summary This review concluded (...) that there was a need for better reporting of harms in randomised controlled trials of antipsychotics for behavioural and psychological symptoms of dementia. This conclusion appears appropriate given the evidence presented. Authors' objectives To evaluate adverse events in relation to antipsychotic medications for behavioural and psychological symptoms of dementia Searching MEDLINE, EMBASE, PsycINFO and Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to 2005. Search terms were reported

DARE.2005

245. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids

Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids Moore R A, McQuay H J CRD summary The review concluded that the majority of patients using opioids for chronic non-malignant pain (...) experience at least one adverse event, and that a significant proportion stop using them because of an adverse event. The conclusion appears to follow from the evidence presented, although lack of detail about the methods and the short duration of the trials make it difficult to verify the findings. Authors' objectives To determine the prevalence of opioid adverse events in chronic non-malignant pain (CNMP); to identify major differences in opioid adverse events in CNMP of different aetiology

DARE.2005

246. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review

Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review Romsing J, Moiniche S, Mathiesen O, Dahl J B CRD summary This review evaluated opioid (...) -related adverse events in studies of opioid sparing with cyclooxygenase-2 (COX-2) inhibitors compared with placebo in post-operative pain. The authors concluded that opioid sparing with COX-2 inhibitors does not have a clinically beneficial effect on opioid-related adverse events. The conclusion appears reliable based on the data presented, although relevant studies might not have been included. Authors' objectives To review opioid-related adverse events in studies of opioid-sparing post-operative

DARE.2005

247. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (...) CRD summary This review evaluated the risk of adverse events associated with testosterone replacement in older men. The authors concluded that testosterone replacement is associated with a significantly higher risk of prostate events and of a haematocrit of more than 50% relative to placebo. A limited search, unclear review methodology, and the unknown quality of the primary studies limit the reliability of the conclusions. Authors' objectives To determine the risk of adverse events associated

DARE.2005

248. Biphasic insulin aspart 30: literature review of adverse events associated with treatment

Biphasic insulin aspart 30: literature review of adverse events associated with treatment Biphasic insulin aspart 30: literature review of adverse events associated with treatment Biphasic insulin aspart 30: literature review of adverse events associated with treatment Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R CRD summary This review assessed the safety of biphasic insulin aspart 30 (BIAsp 30) for patients with diabetes. The authors concluded that the safety profile is comparable (...) studies examined BIAsp 30 as a monotherapy or in conjunction with an oral antidiabetic medication, and used a range of dosing schedules. The comparators were biphasic human insulin 30 (BHI 30), neutral protamine Hagedorn (NPH) insulin and Mix 25. Study duration ranged from a single dose to 2 years. The safety outcomes reported included hypoglycaemic events, major hypoglycaemia, nocturnal hypoglycaemia, minor hypoglycaemia, weight gain and other adverse events. No inclusion criteria for the study

DARE.2005

249. Vitex agnus castus: a systematic review of adverse events

Vitex agnus castus: a systematic review of adverse events Vitex agnus castus: a systematic review of adverse events Vitex agnus castus: a systematic review of adverse events Daniele C, Thompson Coon J, Pittler M H, Ernst E CRD summary This review assessed the safety of Vitex agnus castus (VAC) monopreparations. The authors concluded that the available data indicate that VAC is not associated with serious health risks, but further rigorous studies are needed. The authors' conclusion about (...) adverse event rates may be optimistic given the paucity of well-controlled studies, but the need for further rigorous studies is supported. Authors' objectives To evaluate the safety of Vitex agnus castus (VAC) monopreparations. Searching MEDLINE, AMED, CINAHL, EMBASE, PsycINFO and the Cochrane Library were searched (September 2004) for relevant articles; the search terms were reported and no language restrictions were applied. In addition, personal files and the references of identified articles were

DARE.2005

250. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis

The cost of glucocorticoid-associated adverse events in rheumatoid arthritis The cost of glucocorticoid-associated adverse events in rheumatoid arthritis The cost of glucocorticoid-associated adverse events in rheumatoid arthritis Pisu M, James N, Sampsel S, Saag K G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) were derived from a review and synthesis of published studies, supplemented with authors' assumptions. Link between effectiveness and cost data The costing was carried out retrospectively on the basis of a hypothetical sample of patients. Modelling A Markov model was developed to compare the health care costs. However, it also calculated the number of deaths that resulted from the use and non-use of glucocorticoids. The model incorporated seven health states. Specifically, no adverse events

NHS Economic Evaluation Database.2005

252. The investigation and analysis of critical incidents and adverse events in healthcare

The investigation and analysis of critical incidents and adverse events in healthcare The investigation and analysis of critical incidents and adverse events in healthcare The investigation and analysis of critical incidents and adverse events in healthcare Woloshynowych M, Rogers S, Taylor-Adams S, Vincent C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Woloshynowych M, Rogers S, Taylor-Adams S, Vincent C. The investigation and analysis of critical incidents and adverse events in healthcare. Health Technology Assessment 2005; 9(19): 1-158 Authors' objectives The aim of this report was to carry out a review of published and unpublished work on the analysis on methods of accident investigation in high-risk industries, and of critical incidents in healthcare. To develop and pilot guidelines for the analysis of critical incidents

Health Technology Assessment (HTA) Database.2005

253. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting.

Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Adverse drug events cause substantial morbidity and mortality, yet they remain underappreciated and misunderstood. The terminology to describe errors and patient harm associated with medications causes much confusion. This article uses the case study of a patient with multiple adverse drug events to clarify key terms, such as adverse event, adverse drug reaction, adverse drug event, medication (...) error, and side effect. The case discussion illustrates clinical approaches to analyzing the causal connection between a suspect drug and an adverse event. Examples and rationale for meaningful documentation of adverse drug events are provided, along with an outline of the types of events that should be reported to regulatory agencies.

Annals of Internal Medicine2004

254. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals.

Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. OBJECTIVES: To compare the effectiveness, reliability, and acceptability of estimating rates of adverse events and rates of preventable adverse events using three methods: cross sectional (data gathered in one day), prospective (data gathered during hospital stay), and retrospective (review of medical records). DESIGN: Independent assessment of three methods (...) applied to one sample. SETTING: 37 wards in seven hospitals (three public, four private) in southwestern France. PARTICIPANTS: 778 patients: medical (n = 278), surgical (n = 263), and obstetric (n = 237). MAIN OUTCOME MEASURES: The main outcome measures were the proportion of cases (patients with at least one adverse event) identified by each method compared with a reference list of cases confirmed by ward staff and the proportion of preventable cases (patients with at least one preventable adverse

BMJ2004 Full Text: Link to full Text with Trip Pro

255. Surveillance of medical device-related hazards and adverse events in hospitalized patients.

Surveillance of medical device-related hazards and adverse events in hospitalized patients. CONTEXT: Although adverse drug events have been extensively evaluated by computer-based surveillance, medical device errors have no comparable surveillance techniques. OBJECTIVES: To determine whether computer-based surveillance can reliably identify medical device-related hazards (no known harm to patient) and adverse medical device events (AMDEs; patient experienced harm) and to compare alternative (...) methods of detection of device-related problems. DESIGN, SETTING, AND PARTICIPANTS: This descriptive study was conducted from January through September 2000 at a 520-bed tertiary teaching institution in the United States with experience in using computer tools to detect and prevent adverse drug events. All 20 441 regular and short-stay patients (excluding obstetric and newborn patients) were included. MAIN OUTCOME MEASURES: Medical device events as detected by computer-based flags, telemetry problem

JAMA2004

256. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies Fischbach L A, Van Zanten S V, Dickason J CRD summary This review of the safety and efficacy of first-line anti (...) studies were from 17 different countries. Outcomes assessed in the review Studies were eligible for inclusion if they reported sufficient information to enable the calculation of the proportion of patients cured. The primary outcome of interest was the risk difference between first-line quadruple therapy and no anti-H. pylori therapy. Adverse events and treatment adherence were also investigated. How were decisions on the relevance of primary studies made? Two authors independently assessed full

DARE.2004

257. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence

Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence Jefferson T, Rudin M, Di Pietrantonj C CRD summary The evidence of adverse effects following immunisation with aluminium-containing diphtheria, tetanus and pertussis (DTP (...) aluminium salts or that contained them in different concentrations. Searching Several sources were searched without language restrictions, up to May 2003, including MEDLINE, EMBASE, the Cochrane Library, the Cochrane Vaccines Field Register, DARE, Biological Abstracts, Science Citation Index, and the Vaccine Adverse Event Reporting System website. Search terms were reported. Reference lists of relevant papers and reviews were also searched. Study selection Studies that compared aluminium containing

DARE.2004

258. Adverse drug events in ambulatory care.

Adverse drug events in ambulatory care. BACKGROUND: Adverse events related to drugs occur frequently among inpatients, and many of these events are preventable. However, few data are available on adverse drug events among outpatients. We conducted a study to determine the rates, types, severity, and preventability of such events among outpatients and to identify preventive strategies. METHODS: We performed a prospective cohort study, including a survey of patients and a chart review, at four (...) adult primary care practices in Boston (two hospital-based and two community-based), involving a total of 1202 outpatients who received at least one prescription during a four-week period. Prescriptions were computerized at two of the practices and handwritten at the other two. RESULTS: Of the 661 patients who responded to the survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence interval, 20 to 29 percent), with a total of 181 events (27 per 100 patients

NEJM2003

259. Incidence and preventability of adverse drug events among older persons in the ambulatory setting.

Incidence and preventability of adverse drug events among older persons in the ambulatory setting. CONTEXT: Adverse drug events, especially those that may be preventable, are among the most serious concerns about medication use in older persons cared for in the ambulatory clinical setting. OBJECTIVE: To assess the incidence and preventability of adverse drug events among older persons in the ambulatory clinical setting. DESIGN, SETTING, AND PATIENTS: Cohort study of all Medicare enrollees (30 (...) of administrative incident reports concerning medication errors. MAIN OUTCOME MEASURES: Number of adverse drug events, severity of the events (classified as significant, serious, life-threatening, or fatal), and whether the events were preventable. RESULTS: There were 1523 identified adverse drug events, of which 27.6% (421) were considered preventable. The overall rate of adverse drug events was 50.1 per 1000 person-years, with a rate of 13.8 preventable adverse drug events per 1000 person-years

JAMA2003

260. The incidence and severity of adverse events affecting patients after discharge from the hospital.

The incidence and severity of adverse events affecting patients after discharge from the hospital. BACKGROUND: Studies of hospitalized patients identify safety as a significant problem, but few data are available regarding injuries occurring after discharge. Patients may be vulnerable during this transition period. OBJECTIVE: To describe the incidence, severity, preventability, and "ameliorability" of adverse events affecting patients after discharge from the hospital and to develop strategies (...) for improving patient safety during this interval. DESIGN: Prospective cohort study. SETTING: A tertiary care academic hospital. PATIENTS: 400 consecutive patients discharged home from the general medical service. MEASUREMENTS: The three main outcomes were adverse events, defined as injuries occurring as a result of medical management; preventable adverse events, defined as adverse events judged to have been caused by an error; and ameliorable adverse events, defined as adverse events whose severity could

Annals of Internal Medicine2003